Xanthoma disseminatum

Xanthoma disseminatum (XD), also known as Montgomery syndrome, is a rare non-Langerhans cell histiocytosis characterized by the widespread development of yellowish-brown or reddish-brown papules and nodules on the skin, mucous membranes, and sometimes internal organs. It is classified as a benign proliferative disorder of non-Langerhans histiocytes (macrophages) and is considered a normolipemic condition, meaning blood lipid levels are typically normal despite the xanthomatous skin lesions. The disease primarily affects the skin, with lesions favoring flexural areas such as the axillae, groin, antecubital fossae, and eyelids. Mucosal involvement of the upper respiratory tract, oral cavity, and conjunctivae is common and can lead to significant complications including airway obstruction. A hallmark feature of XD is the potential involvement of the central nervous system, particularly the hypothalamic-pituitary axis, which can result in diabetes insipidus in approximately 40% of patients. Other organ systems that may be affected include the lungs, liver, kidneys, and bones. Xanthoma disseminatum typically presents in young adult males, though cases have been reported across all ages including childhood. The clinical course is variable: some patients experience spontaneous resolution, while others have a chronic progressive course. There is no established curative treatment. Management is largely supportive and symptom-directed. Therapeutic approaches that have been tried with variable success include surgical excision, laser therapy, lipid-lowering agents (such as statins and fibrates despite normal lipid levels), systemic corticosteroids, cyclophosphamide, cladribine (2-chlorodeoxyadenosine), and radiotherapy for localized lesions. Diabetes insipidus, when present, is managed with desmopressin (DDAVP). Given the rarity of the condition, treatment decisions are typically individualized based on disease severity and organ involvement.

Common questions about Xanthoma disseminatum